A large proportion of patients with non-small cell lung cancer (NSCLC) have mutations in EGFR, making it a popular target for novel therapeutics. In this podcast, we hear from Prof. Charles Swanton, Dr Emilia Lim, Prof. Sanjay Popat, Dr Qing Zhou, Dr Hazel O’Sullivan, Dr Julia Rotow, and Dr Biagio Ricciuti, as they discuss some of the latest clinical trial data in this field, as well as perspectives on molecular testing and new research into the causes of EGFR-mutant lung cancer.